Immunotherapy company Innate Pharma SA (Euronext Paris: IPH) (Nasdaq: IPHA) on Monday announced updated results from the Phase 1/2 trial of SAR443579/IPH6101 (SAR'579), a first-in-class NK cell engager targeting CD123.
Developed under a joint research collaboration with Sanofi (Nasdaq: SNY), the investigational drug is being tested for relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), and high-risk myelodysplasia (HR-MDS).
Presented at the European Hematology Association 2024 Congress on 16 June 2024, the data revealed that SAR'579 achieved five complete remissions (four CR, one CRi) at a 1 mg/kg dose, with three patients showing durable complete remission for over 10 months. SAR'579 demonstrated a favorable safety profile, tolerated at doses up to 6 mg/kg.
The study treated 59 patients, mostly with R/R AML, across 11 dose levels. A median treatment duration of 7.9 weeks was reported, and two patients remained on maintenance therapy as of the data cutoff. These findings will inform the recommended doses for the Phase 2 trial.
SAR'579 is part of Innate's ANKET platform, which focuses on developing multi-specific NK cell engagers to treat cancer. Innate and Sanofi's collaboration includes a research agreement from 2016, under which Innate could receive up to EUR400m in milestone payments and royalties on net sales.
Under a license agreement entered in December 2022, Sanofi licensed IPH62 and IPH67 and has the option for one additional target. According to the terms of the 2022 agreement, Innate Pharma is eligible to up to EUR1.35bn in development and commercial milestone payments as well as royalties on net sales.
Innate Pharma, headquartered in Marseille, France, with a US office in Rockville, MD, specialises in developing immunotherapies for cancer, with partnerships including Sanofi and AstraZeneca.
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma